Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
New data illuminates research in osteoporosis
March 24th, 2005
Data on osteoporosis are outlined in reports from Italy, Japan and Finland. Study 1: Raloxifene was found to modulate interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha synthesis in in vivo studies. "Raloxifene (RAL), a selective estrogen receptor modulator, is indicated for the prevention and treatment of postmenopausal osteoporosis. RAL, by decreasing bone turnover, prevents bone loss and microarchitecture damage, reducing the incidence of osteoporotic fractures," explained W. Gianni and colleagues, University of Roma La Sapienza. "Our previous in vitro data demonstrated that RAL modulates osteoclast activity by, at least in part, an IL-6-...
Source: Women's Health Weekly (2005-03-24)
|
